HealthCare Global Enterprises (HCG) HCG
India's largest listed cancer-care network (HCG cancer centres) plus Milann fertility clinics; KKR took control from CVC in 2025
Mapped in 1 theme: Hospitals & Healthcare.
Where HealthCare Global Enterprises (HCG) sits in the supply chain
HealthCare Global Enterprises (HCG) appears in 1 supply-chain layer in one theme, Hospitals & Healthcare.
Hospitals & Healthcare › Single-specialty chains
OperatorOther companies in this layer
Revenue and profit
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1,395 | 1,691 | 1,908 | 2,218 | 2,538 |
| Net profit | 39 | 18 | 41 | 49 | 23 |
Latest-year revenue ₹2,538 Cr (FY26, company-wide).
Strengths
- Oncology is the fastest-growing high-acuity specialty
- Equipment-heavy radiation and nuclear medicine create a moat
- KKR ownership brings capital for expansion
Risks
- High capex and leases keep returns on capital modest
- Some centres are still ramping up
- Cancer-drug mark-ups are central to the Supreme Court case
Common questions
What does HealthCare Global Enterprises (HCG) do?
India's largest listed cancer-care network (HCG cancer centres) plus Milann fertility clinics; KKR took control from CVC in 2025.
Where does HealthCare Global Enterprises (HCG) sit in the supply chain?
HealthCare Global Enterprises (HCG) (NSE: HCG) is mapped in 1 supply-chain layer: Single-specialty chains (Hospitals & Healthcare).
Who are HealthCare Global Enterprises (HCG)'s peers?
In the Single-specialty chains layer of Hospitals & Healthcare: Dr Agarwal's Health Care, Rainbow Children's Medicare, Shalby, Indira IVF (not NSE-listed) and Cloudnine Hospitals (not NSE-listed).
What is HealthCare Global Enterprises (HCG)'s market cap and valuation?
As of 6 Nov 2026: market cap ₹8,957 Cr, P/E 226.0x, ROCE 8.3%, ROE 2.5%, dividend yield 0%.